ArticlePharmacoEconomics2021
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.
Article in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- System dynamics modelling methods for public health policy evaluation: a systematic literature review focussing on mental health and substance use disorders.BMC public health · 2026Pooled it
- Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital.Journal of comparative effectiveness research · 2026Review
- The 'Values in Modelling' Framework for Patient and Public Involvement in Health Economics Modelling: Development and Application in the LEAP Model Project.PharmacoEconomics · 2026Review
- The involvement of stakeholders in computational model development to support decision-making in public health: a scoping review.BMC public health · 2025Article
- Enhancing Patient Engagement in HTA: Using Consensus Research to Overcome PICO Scoping Challenges Under the EU HTAR.Journal of market access & health policy · 2025Article
- Article
- A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete.PharmacoEconomics · 2025Article
- Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review.Health economics review · 2024Review
- Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement.PharmacoEconomics · 2024Article
- Implementing Strengths-Based Dialogue to Reframe Clinical Education and Community Engagement.Perspectives of the ASHA special interest groups · 2023Article
- Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease.PharmacoEconomics - open · 2023Article
- Values in Modelling: Video Series Development and Evaluation Survey.Applied health economics and health policy · 2023Article
- Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance.PharmacoEconomics · 2023Article
- Stakeholder Engagement in the Development of Public Health Economic Models: An Application to Modelling of Minimum Unit Pricing of Alcohol in South Africa.Applied health economics and health policy · 2023Article
- Civil society and medical product access in Africa: Lessons from COVID-19.Frontiers in medical technology · 2023Article
- Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.PharmacoEconomics · 2022Article
- Four Aspects Affecting Health Economic Decision Models and Their Validation.PharmacoEconomics · 2022Article
- Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency.PharmacoEconomics · 2022Article
- Economic analyses of behavioral health intervention implementation: Perspective on stakeholder engagement.Frontiers in psychiatry · 2022Article
- The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers.PharmacoEconomics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While evidence generated from health economic (HE) models is being used more commonly in health technology assessment (HTA) in the US, it is not consistently adopted by different stakeholder groups or across therapeutic areas. We hypothesize that actively engaging with multiple stakeholder groups throughout the model development process may result in models more widely considered by decision makers. To test this hypothesis, the Innovation and Value Initiative has launched a modeling effort to build an open-source HE model focusing on the disease state 'major depressive disorder'. A 20-member advisory group has been formed with representatives from patients, employers, clinicians, innovators, payers, and researchers to guide the model development process. While this effort is still in the early stages, the ongoing stakeholder engagement effort has yielded valuable insights that inform the model design. We have also identified several challenges to implementing this new approach. Our early findings suggest that the stakeholder engagement approach to HE model development has the potential to improve HTA in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.